Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTL008.16 in advanced solid tumors
NCT06410131Phase 1Recruiting
- Sponsor
- Sound Biopharmaceuticals
- Start
- May 2025
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of FTL-008.16 in solid tumor (2 arms), sponsored by Sound Biopharmaceuticals. Primary endpoint: Number of participants with dose-limiting toxicities at 28 days. Started May 2025; status: recruiting.
02
Drugs
FTL-008.16
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06410131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06410131.